Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States.
Drugs - real world outcomes June 1, 2024 Lisa Harding, Kruti Joshi, Maryia Zhdanava et al. 5 citations
Adults with treatment-resistant depression who completed induction treatment with esketamine nasal spray showed reductions in acute healthcare costs, particularly among those who had prior mental health-related hospitalizations or emergency visits. In a cohort of 322 patients, mean all-cause acute healthcare costs per patient per month fell from $837 before treatment to $770 after, while mental health-related costs dropped from $648 to $577. Among 111 patients with prior acute care use, all-cause costs decreased from $2,323 to $1,423, driven by mental health-related cost reductions from $1,880 to $1,139. Patients generally took longer than the label-recommended 28 days to complete the eight induction sessions, averaging 73 days. Most patients continued with maintenance sessions.